Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 12 March, 2025
Author: Getaka|Social: Getaka Financial Technology X (Earlier Twitter) Profile Getaka Financial Technology LinkedIn Logo
Stock Ticker - BSE: 506414 | NSE: FERMENTA

Fermenta Biotech Ltd: Share Price Analysis, Intrinsic Value & Fundamentals (2025)

Share Price and Basic Stock Data

Last Updated: March 11, 2025, 10:42 pm

Market Cap 746 Cr.
Current Price 254
High / Low 449/145
Stock P/E21.2
Book Value 98.6
Dividend Yield0.49 %
ROCE3.20 %
ROE5.59 %
Face Value 5.00
PEG Ratio-4.39

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Fermenta Biotech Ltd

Competitors of Fermenta Biotech Ltd

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
MPS Pharmaa Ltd 6.71 Cr. 3.51 4.33/3.05 0.800.00 %9.15 %34.9 % 10.0
Gujarat Themis Biosyn Ltd 2,663 Cr. 244 390/19250.6 20.50.27 %45.0 %33.8 % 1.00
Gujarat Terce Laboratories Ltd 53.1 Cr. 71.5 94.9/32.118.0 11.90.00 %9.72 %3.44 % 10.0
Gujarat Inject (Kerala) Ltd 38.0 Cr. 26.0 29.0/8.7438.8 6.640.00 %2.65 %2.08 % 10.0
Godavari Drugs Ltd 70.4 Cr. 93.5 155/79.011.4 55.40.00 %14.4 %15.5 % 10.0
Industry Average17,255.37 Cr1,081.8442.42185.800.37%16.00%16.32%6.27

All Competitor Stocks of Fermenta Biotech Ltd

Quarterly Result

MetricDec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Sales 9396929855105825799977895156
Expenses 917887956586727174927776103
Operating Profit 21853-101911-1425511953
OPM % 2%18%5%3%-18%18%13%-24%25%6%1%20%34%
Other Income 1343-19-82-635332
Interest 4445565453344
Depreciation 7679666666666
Profit before tax -710-2-8-41-12-29161-61245
Tax % 13%21%8%6%-8%373%0%0%38%885%0%6%16%
Net Profit -88-3-8-38-52-2910-7-61138
EPS in Rs -2.732.61-0.88-2.75-12.70-1.400.62-9.703.35-2.36-1.983.8712.54

Last Updated: March 4, 2025, 12:20 pm

Below is a detailed analysis of the quarterly data for Fermenta Biotech Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

  • For Sales, as of Dec 2024, the value is ₹156.00 Cr.. The value appears strong and on an upward trend. It has increased from 95.00 Cr. (Sep 2024) to ₹156.00 Cr., marking an increase of ₹61.00 Cr..
  • For Expenses, as of Dec 2024, the value is ₹103.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 76.00 Cr. (Sep 2024) to ₹103.00 Cr., marking an increase of ₹27.00 Cr..
  • For Operating Profit, as of Dec 2024, the value is ₹53.00 Cr.. The value appears strong and on an upward trend. It has increased from 19.00 Cr. (Sep 2024) to ₹53.00 Cr., marking an increase of ₹34.00 Cr..
  • For OPM %, as of Dec 2024, the value is 34.00%. The value appears strong and on an upward trend. It has increased from 20.00% (Sep 2024) to 34.00%, marking an increase of 14.00%.
  • For Other Income, as of Dec 2024, the value is ₹2.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3.00 Cr. (Sep 2024) to ₹2.00 Cr., marking a decrease of 1.00 Cr..
  • For Interest, as of Dec 2024, the value is ₹4.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 4.00 Cr..
  • For Depreciation, as of Dec 2024, the value is ₹6.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 6.00 Cr..
  • For Profit before tax, as of Dec 2024, the value is ₹45.00 Cr.. The value appears strong and on an upward trend. It has increased from 12.00 Cr. (Sep 2024) to ₹45.00 Cr., marking an increase of ₹33.00 Cr..
  • For Tax %, as of Dec 2024, the value is 16.00%. The value appears to be increasing, which may not be favorable. It has increased from 6.00% (Sep 2024) to 16.00%, marking an increase of 10.00%.
  • For Net Profit, as of Dec 2024, the value is ₹38.00 Cr.. The value appears strong and on an upward trend. It has increased from 11.00 Cr. (Sep 2024) to ₹38.00 Cr., marking an increase of ₹27.00 Cr..
  • For EPS in Rs, as of Dec 2024, the value is 12.54. The value appears strong and on an upward trend. It has increased from ₹3.87 (Sep 2024) to 12.54, marking an increase of ₹8.67.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 7, 2025, 4:03 pm

MetricMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024TTM
Sales 117139142155164302403292376397349335427
Expenses 94113126134152209248225293335330307349
Operating Profit 232616211293156668362182878
OPM % 20%19%11%13%7%31%39%23%22%16%5%8%18%
Other Income 23013961288-20413
Interest 5546101421201918211715
Depreciation 91098101212152026282525
Profit before tax 101437-676129435227-51-1052
Tax % 36%24%67%61%49%28%8%-37%18%44%4%143%
Net Profit 41012-946117604315-53-2436
EPS in Rs 1.512.860.17-0.41-4.1412.2142.7120.2315.465.25-17.36-7.8412.07
Dividend Payout % 124%29%249%-51%-5%2%1%24%16%23%-7%-16%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2013-20142014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-2024
YoY Net Profit Growth (%)150.00%-90.00%100.00%-550.00%611.11%154.35%-48.72%-28.33%-65.12%-453.33%54.72%
Change in YoY Net Profit Growth (%)0.00%-240.00%190.00%-650.00%1161.11%-456.76%-203.07%20.38%-36.78%-388.22%508.05%

Fermenta Biotech Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

No data available for the compounded sales growth chart.

Balance Sheet

Last Updated: December 14, 2024, 1:43 pm

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Sep 2024
Equity Capital 2222225141414141414
Reserves 125130129128142122246295346358301274276
Borrowings 4365718987173209224232239220139125
Other Liabilities 55616070758792809496102120125
Total Liabilities 226259262288307385551614687707637548539
Fixed Assets 948785168172177178200263299267269258
CWIP 153665654227157354526
Investments 1117181518108000300
Other Assets 1051189499112193344342367373321277274
Total Assets 226259262288307385551614687707637548539

Below is a detailed analysis of the balance sheet data for Fermenta Biotech Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

  • For Equity Capital, as of Sep 2024, the value is ₹14.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹14.00 Cr..
  • For Reserves, as of Sep 2024, the value is ₹276.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹274.00 Cr. (Mar 2024) to ₹276.00 Cr., marking an increase of 2.00 Cr..
  • For Borrowings, as of Sep 2024, the value is ₹125.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from ₹139.00 Cr. (Mar 2024) to ₹125.00 Cr., marking a decrease of 14.00 Cr..
  • For Other Liabilities, as of Sep 2024, the value is ₹125.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹120.00 Cr. (Mar 2024) to ₹125.00 Cr., marking an increase of 5.00 Cr..
  • For Total Liabilities, as of Sep 2024, the value is ₹539.00 Cr.. The value appears to be improving (decreasing). It has decreased from ₹548.00 Cr. (Mar 2024) to ₹539.00 Cr., marking a decrease of 9.00 Cr..
  • For Fixed Assets, as of Sep 2024, the value is ₹258.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹269.00 Cr. (Mar 2024) to ₹258.00 Cr., marking a decrease of 11.00 Cr..
  • For CWIP, as of Sep 2024, the value is ₹6.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹2.00 Cr. (Mar 2024) to ₹6.00 Cr., marking an increase of 4.00 Cr..
  • For Investments, as of Sep 2024, the value is ₹0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹0.00 Cr..
  • For Other Assets, as of Sep 2024, the value is ₹274.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹277.00 Cr. (Mar 2024) to ₹274.00 Cr., marking a decrease of 3.00 Cr..
  • For Total Assets, as of Sep 2024, the value is ₹539.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹548.00 Cr. (Mar 2024) to ₹539.00 Cr., marking a decrease of 9.00 Cr..

Notably, the Reserves (₹276.00 Cr.) exceed the Borrowings (125.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

No data available for this post.

Free Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Free Cash Flow-20.00-39.00-55.00-68.00-75.00-80.00-53.00-158.00-149.00-177.00-202.00-111.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days79106911019983598766804476
Inventory Days225149125160208234347594441380309245
Days Payable13412095113147183169260169154109182
Cash Conversion Cycle171136122148160134237421338306244139
Working Capital Days72734201159097202171180123108
ROCE %8%9%3%6%2%31%41%12%13%7%-0%3%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthDec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
Promoters59.58%59.58%59.58%59.58%59.58%59.58%62.06%62.06%62.06%62.06%62.06%62.06%
FIIs0.01%0.01%0.01%0.01%0.01%0.00%0.00%0.00%0.00%0.00%0.00%0.05%
DIIs0.05%0.05%0.05%0.05%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Public38.37%38.37%38.37%38.38%38.45%38.46%36.00%36.04%36.05%36.05%36.11%36.41%
Others1.98%1.98%1.98%1.98%1.95%1.95%1.92%1.89%1.89%1.89%1.82%1.47%
No. of Shareholders18,57817,51817,47217,97117,61016,89716,14815,72115,15015,17814,58913,221

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue 5.005.005.005.005.00
Basic EPS (Rs.) -7.99-17.855.3315.7720.63
Diluted EPS (Rs.) -7.99-17.855.3315.6920.63
Cash EPS (Rs.) 0.24-8.7714.0821.7825.83
Book Value[Excl.RevalReserv]/Share (Rs.) 98.76108.08128.76124.90107.27
Book Value[Incl.RevalReserv]/Share (Rs.) 98.76108.08128.76124.90107.27
Revenue From Operations / Share (Rs.) 116.25121.27138.15130.79101.55
PBDIT / Share (Rs.) 13.628.8824.1231.1726.89
PBIT / Share (Rs.) 5.06-0.9015.2624.1321.69
PBT / Share (Rs.) -3.42-17.989.3417.9015.05
Net Profit / Share (Rs.) -8.31-18.565.2214.7420.63
NP After MI And SOA / Share (Rs.) -7.99-17.855.3515.7720.63
PBDIT Margin (%) 11.717.3217.4623.8326.47
PBIT Margin (%) 4.34-0.7411.0418.4421.35
PBT Margin (%) -2.94-14.826.7613.6814.82
Net Profit Margin (%) -7.15-15.303.7711.2720.31
NP After MI And SOA Margin (%) -6.86-14.713.8712.0620.31
Return on Networth / Equity (%) -7.98-16.364.1512.6219.23
Return on Capital Employeed (%) 3.89-0.618.8114.5614.92
Return On Assets (%) -4.20-8.092.186.629.69
Long Term Debt / Equity (X) 0.140.260.300.300.32
Total Debt / Equity (X) 0.450.680.630.570.66
Asset Turnover Ratio (%) 0.560.520.550.570.51
Current Ratio (X) 1.401.211.521.481.46
Quick Ratio (X) 0.890.580.740.700.79
Inventory Turnover Ratio (X) 0.700.770.911.061.02
Dividend Payout Ratio (NP) (%) -15.65-7.0046.680.0012.09
Dividend Payout Ratio (CP) (%) 217.49-15.5017.580.009.65
Earning Retention Ratio (%) 115.65107.0053.320.0087.91
Cash Earning Retention Ratio (%) -117.49115.5082.420.0090.35
Interest Coverage Ratio (X) 2.311.234.075.004.05
Interest Coverage Ratio (Post Tax) (X) 0.02-0.201.883.374.11
Enterprise Value (Cr.) 505.89464.45795.24883.96786.75
EV / Net Operating Revenue (X) 1.511.332.002.342.69
EV / EBITDA (X) 12.8718.1211.439.8310.14
MarketCap / Net Operating Revenue (X) 1.300.881.491.912.09
Retention Ratios (%) 115.65107.0053.310.0087.90
Price / BV (X) 1.510.981.592.001.98
Price / Net Operating Revenue (X) 1.300.881.491.912.10
EarningsYield -0.05-0.160.020.060.09

After reviewing the key financial ratios for Fermenta Biotech Ltd, here is a detailed analysis based on the latest available data and recent trends:

  • For FaceValue, as of Mar 24, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 5.00.
  • For Basic EPS (Rs.), as of Mar 24, the value is -7.99. This value is below the healthy minimum of 5. It has increased from -17.85 (Mar 23) to -7.99, marking an increase of 9.86.
  • For Diluted EPS (Rs.), as of Mar 24, the value is -7.99. This value is below the healthy minimum of 5. It has increased from -17.85 (Mar 23) to -7.99, marking an increase of 9.86.
  • For Cash EPS (Rs.), as of Mar 24, the value is 0.24. This value is below the healthy minimum of 3. It has increased from -8.77 (Mar 23) to 0.24, marking an increase of 9.01.
  • For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 98.76. It has decreased from 108.08 (Mar 23) to 98.76, marking a decrease of 9.32.
  • For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 98.76. It has decreased from 108.08 (Mar 23) to 98.76, marking a decrease of 9.32.
  • For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 116.25. It has decreased from 121.27 (Mar 23) to 116.25, marking a decrease of 5.02.
  • For PBDIT / Share (Rs.), as of Mar 24, the value is 13.62. This value is within the healthy range. It has increased from 8.88 (Mar 23) to 13.62, marking an increase of 4.74.
  • For PBIT / Share (Rs.), as of Mar 24, the value is 5.06. This value is within the healthy range. It has increased from -0.90 (Mar 23) to 5.06, marking an increase of 5.96.
  • For PBT / Share (Rs.), as of Mar 24, the value is -3.42. This value is below the healthy minimum of 0. It has increased from -17.98 (Mar 23) to -3.42, marking an increase of 14.56.
  • For Net Profit / Share (Rs.), as of Mar 24, the value is -8.31. This value is below the healthy minimum of 2. It has increased from -18.56 (Mar 23) to -8.31, marking an increase of 10.25.
  • For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is -7.99. This value is below the healthy minimum of 2. It has increased from -17.85 (Mar 23) to -7.99, marking an increase of 9.86.
  • For PBDIT Margin (%), as of Mar 24, the value is 11.71. This value is within the healthy range. It has increased from 7.32 (Mar 23) to 11.71, marking an increase of 4.39.
  • For PBIT Margin (%), as of Mar 24, the value is 4.34. This value is below the healthy minimum of 10. It has increased from -0.74 (Mar 23) to 4.34, marking an increase of 5.08.
  • For PBT Margin (%), as of Mar 24, the value is -2.94. This value is below the healthy minimum of 10. It has increased from -14.82 (Mar 23) to -2.94, marking an increase of 11.88.
  • For Net Profit Margin (%), as of Mar 24, the value is -7.15. This value is below the healthy minimum of 5. It has increased from -15.30 (Mar 23) to -7.15, marking an increase of 8.15.
  • For NP After MI And SOA Margin (%), as of Mar 24, the value is -6.86. This value is below the healthy minimum of 8. It has increased from -14.71 (Mar 23) to -6.86, marking an increase of 7.85.
  • For Return on Networth / Equity (%), as of Mar 24, the value is -7.98. This value is below the healthy minimum of 15. It has increased from -16.36 (Mar 23) to -7.98, marking an increase of 8.38.
  • For Return on Capital Employeed (%), as of Mar 24, the value is 3.89. This value is below the healthy minimum of 10. It has increased from -0.61 (Mar 23) to 3.89, marking an increase of 4.50.
  • For Return On Assets (%), as of Mar 24, the value is -4.20. This value is below the healthy minimum of 5. It has increased from -8.09 (Mar 23) to -4.20, marking an increase of 3.89.
  • For Long Term Debt / Equity (X), as of Mar 24, the value is 0.14. This value is below the healthy minimum of 0.2. It has decreased from 0.26 (Mar 23) to 0.14, marking a decrease of 0.12.
  • For Total Debt / Equity (X), as of Mar 24, the value is 0.45. This value is within the healthy range. It has decreased from 0.68 (Mar 23) to 0.45, marking a decrease of 0.23.
  • For Asset Turnover Ratio (%), as of Mar 24, the value is 0.56. It has increased from 0.52 (Mar 23) to 0.56, marking an increase of 0.04.
  • For Current Ratio (X), as of Mar 24, the value is 1.40. This value is below the healthy minimum of 1.5. It has increased from 1.21 (Mar 23) to 1.40, marking an increase of 0.19.
  • For Quick Ratio (X), as of Mar 24, the value is 0.89. This value is below the healthy minimum of 1. It has increased from 0.58 (Mar 23) to 0.89, marking an increase of 0.31.
  • For Inventory Turnover Ratio (X), as of Mar 24, the value is 0.70. This value is below the healthy minimum of 4. It has decreased from 0.77 (Mar 23) to 0.70, marking a decrease of 0.07.
  • For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is -15.65. This value is below the healthy minimum of 20. It has decreased from -7.00 (Mar 23) to -15.65, marking a decrease of 8.65.
  • For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 217.49. This value exceeds the healthy maximum of 50. It has increased from -15.50 (Mar 23) to 217.49, marking an increase of 232.99.
  • For Earning Retention Ratio (%), as of Mar 24, the value is 115.65. This value exceeds the healthy maximum of 70. It has increased from 107.00 (Mar 23) to 115.65, marking an increase of 8.65.
  • For Cash Earning Retention Ratio (%), as of Mar 24, the value is -117.49. This value is below the healthy minimum of 40. It has decreased from 115.50 (Mar 23) to -117.49, marking a decrease of 232.99.
  • For Interest Coverage Ratio (X), as of Mar 24, the value is 2.31. This value is below the healthy minimum of 3. It has increased from 1.23 (Mar 23) to 2.31, marking an increase of 1.08.
  • For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 0.02. This value is below the healthy minimum of 3. It has increased from -0.20 (Mar 23) to 0.02, marking an increase of 0.22.
  • For Enterprise Value (Cr.), as of Mar 24, the value is 505.89. It has increased from 464.45 (Mar 23) to 505.89, marking an increase of 41.44.
  • For EV / Net Operating Revenue (X), as of Mar 24, the value is 1.51. This value is within the healthy range. It has increased from 1.33 (Mar 23) to 1.51, marking an increase of 0.18.
  • For EV / EBITDA (X), as of Mar 24, the value is 12.87. This value is within the healthy range. It has decreased from 18.12 (Mar 23) to 12.87, marking a decrease of 5.25.
  • For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 1.30. This value is within the healthy range. It has increased from 0.88 (Mar 23) to 1.30, marking an increase of 0.42.
  • For Retention Ratios (%), as of Mar 24, the value is 115.65. This value exceeds the healthy maximum of 70. It has increased from 107.00 (Mar 23) to 115.65, marking an increase of 8.65.
  • For Price / BV (X), as of Mar 24, the value is 1.51. This value is within the healthy range. It has increased from 0.98 (Mar 23) to 1.51, marking an increase of 0.53.
  • For Price / Net Operating Revenue (X), as of Mar 24, the value is 1.30. This value is within the healthy range. It has increased from 0.88 (Mar 23) to 1.30, marking an increase of 0.42.
  • For EarningsYield, as of Mar 24, the value is -0.05. This value is below the healthy minimum of 5. It has increased from -0.16 (Mar 23) to -0.05, marking an increase of 0.11.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Fermenta Biotech Ltd as of March 12, 2025 is: ₹93.94

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of March 12, 2025, Fermenta Biotech Ltd is Overvalued by 63.02% compared to the current share price 254.00

Intrinsic Value of Fermenta Biotech Ltd as of March 12, 2025 is: 89.40

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of March 12, 2025, Fermenta Biotech Ltd is Overvalued by 64.80% compared to the current share price 254.00

Last 5 Year EPS CAGR: -4.83%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The company has higher reserves (220.92 cr) compared to borrowings (147.38 cr), indicating strong financial stability.
  2. The company has shown consistent growth in sales (276.77 cr) and profit (26.62 cr) over the years.
  1. The stock has a low average ROCE of 11.25%, which may not be favorable.
  2. The stock has a high average Working Capital Days of 104.58, which may not be favorable.
  3. The stock has a high average Cash Conversion Cycle of 213.00, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Fermenta Biotech Ltd:
    1. Net Profit Margin: -7.15%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 3.89% (Industry Average ROCE: 15.87%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: -7.98% (Industry Average ROE: 15.78%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 0.02
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 0.89
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 21.2 (Industry average Stock P/E: 34.01)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.45
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Fermenta Biotech Ltd. is a Public Limited Listed company incorporated on 01/05/1951 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L99999MH1951PLC008485 and registration number is 008485. Currently Company is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company's Total Operating Revenue is Rs. 307.09 Cr. and Equity Capital is Rs. 14.44 Cr. for the Year ended 31/03/2024.
INDUSTRYADDRESSCONTACT
PharmaceuticalsA-1501, Thane One, Thane Maharashtra 400610info@fermentabiotech.com
https://fermentabiotech.com
Management
NamePosition Held
Mr. Pradeep M ChandanChairman & Ind.Dire (Non-Exe)
Mr. Krishna DatlaExe.Vice Chairman & Whole Time Director
Mr. Prashant NagreManaging Director
Mr. Satish VarmaExecutive Director
Ms. Anupama Datla DesaiExecutive Director
Ms. Rajeshwari DatlaNon Executive Director
Mr. Pramod KasatInd. Non-Executive Director
Ms. Rajashri OjhaInd. Non-Executive Director

FAQ

What is the latest intrinsic value of Fermenta Biotech Ltd?

The latest intrinsic value of Fermenta Biotech Ltd as on 12 March 2025 is ₹93.94, which is 63.02% lower than the current market price of 254.00, indicating the stock is overvalued by 63.02%. The intrinsic value of Fermenta Biotech Ltd is calculated using PE ratio method. The stock has a market capitalization of ₹746 Cr. and recorded a high/low of ₹449/145 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹276 Cr and total liabilities of ₹539 Cr.

What is the Market Cap of Fermenta Biotech Ltd?

The Market Cap of Fermenta Biotech Ltd is 746 Cr..

What is the current Stock Price of Fermenta Biotech Ltd as on 12 March 2025?

The current stock price of Fermenta Biotech Ltd as on 12 March 2025 is ₹254.

What is the High / Low of Fermenta Biotech Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of Fermenta Biotech Ltd stocks is ₹449/145.

What is the Stock P/E of Fermenta Biotech Ltd?

The Stock P/E of Fermenta Biotech Ltd is 21.2.

What is the Book Value of Fermenta Biotech Ltd?

The Book Value of Fermenta Biotech Ltd is 98.6.

What is the Dividend Yield of Fermenta Biotech Ltd?

The Dividend Yield of Fermenta Biotech Ltd is 0.49 %.

What is the ROCE of Fermenta Biotech Ltd?

The ROCE of Fermenta Biotech Ltd is 3.20 %.

What is the ROE of Fermenta Biotech Ltd?

The ROE of Fermenta Biotech Ltd is 5.59 %.

What is the Face Value of Fermenta Biotech Ltd?

The Face Value of Fermenta Biotech Ltd is 5.00.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Fermenta Biotech Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE